United States drugmaker adopts NVIDIA Vera Rubin supercomputer
PUBLISHED Jul 20, 2026, 3:20 PM ET
Read, Watch or Listen
On July 20, 2026, Bristol Myers Squibb (BMS), a global biopharmaceutical company based in the United States, announced an expanded partnership with NVIDIA to significantly scale its artificial intelligence capabilities for drug discovery. BMS will deploy an NVIDIA DGX SuperPOD powered by next-generation DGX Vera Rubin NVL72 systems, described as the most powerful and energy-efficient single-owned NVIDIA compute infrastructure in the life sciences sector. The Vera Rubin architecture, which succeeds NVIDIA’s Blackwell and Hopper platforms, is designed to deliver up to a tenfold increase in performance per megawatt, enabling BMS to run large, complex AI workloads while constraining energy use and operational costs.
By Michael Grant | JQJO News
Timeline of Events
- 2023 BMS completes three-year NVIDIA collaboration
- Early 2026 NVIDIA unveils Vera Rubin architecture
- Early 2026 BMS evaluates next-generation AI hardware
- July 20, 2026 BMS announces expanded NVIDIA partnership
- July 20, 2026 Company confirms DGX SuperPOD deployment
- July 20, 2026 Vera Rubin NVL72 systems selected
- Following months BMS transitions core discovery workflows
- Future years AI supports large-scale foundation model training
News Intelligence
- This partnership could speed up drug discovery, potentially leading to faster treatments for various diseases. If you or a loved one are waiting for medical breakthroughs, this could be promising news. Keep an eye on BMS's announcements for updates.
Comments